The Potential of Cancer Biomarkers
From Discovery to Clinical Application
- 1st Edition - April 14, 2025
- Imprint: Elsevier
- Editor: Pranav Kumar Prabhakar
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 2 7 9 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 2 8 0 - 4
The Potential of Biomarkers: From Discovery to Clinical Application addresses the challenges related to knowledge dissemination, interdisciplinary understanding, diagnostic comple… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Potential of Biomarkers: From Discovery to Clinical Application addresses the challenges related to knowledge dissemination, interdisciplinary understanding, diagnostic complexity, quality assurance, patient care, research advancement, education, and professional development within the field of clinical biochemistry. The book provides a holistic solution by offering comprehensive insights and practical guidance to a diverse audience, contributing to the enhancement of healthcare and biomedical research. Each chapter explores the multifaceted landscape of biomarker research, offering a wealth of insights and expertise in genomics, proteomics, metabolomics, and more.
Cancer biomarkers, the molecular signatures of cancer, hold immense promise in revolutionizing how we diagnose, treat, and personalize therapies for cancer patients. In this curated reference, esteemed contributors explore the multifaceted landscape of biomarker research, offering a wealth of insights and expertise in genomics, proteomics, metabolomics, and more.
Cancer biomarkers, the molecular signatures of cancer, hold immense promise in revolutionizing how we diagnose, treat, and personalize therapies for cancer patients. In this curated reference, esteemed contributors explore the multifaceted landscape of biomarker research, offering a wealth of insights and expertise in genomics, proteomics, metabolomics, and more.
- Presents the impact of biomarkers on early detection, prognosis, and personalized treatment strategies
- Incudes ethical and regulatory considerations surrounding biomarker use, guiding policymakers and ethicists through the complex terrain of biomarker-driven healthcare decisions
- Highlights the clinical relevance of cancer biomarkers by showcasing real-world case studies and examples of how biomarkers have been utilized to improve cancer diagnosis, personalize treatment plans, and monitor treatment responses
Healthcare professionals, clinical laboratory technicians, researchers, educators, clinicians in specialties, anyone in the field of clinical biochemistry
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Preface
- Introduction
- Chapter 1 Introduction: navigating the landscape of cancer biomarkers
- Abstract
- 1.1 Introduction to cancer—a global health issue
- 1.2 The beginnings of cancer—carcinogenesis
- 1.3 The common types of cancer
- 1.4 Introduction to biomarkers
- 1.5 Categories of biomarkers in cancer
- 1.6 Features of biomarker genes
- 1.7 Liver cancer and biomarkers
- 1.8 Antigens and biomarkers
- 1.9 Conclusion
- References
- Chapter 2 Understanding the role of biomarkers in cancer
- Abstract
- 2.1 Introduction
- 2.2 Types of biomarkers in cancer
- 2.3 Genetic biomarkers
- 2.4 Protein biomarkers
- 2.5 Circulating biomarkers
- 2.6 Imaging biomarker
- 2.7 Biomarker discovery, validation, and verification
- 2.8 Biomarker discovery
- 2.9 Biomarker verification
- 2.10 Biomarker validation
- 2.11 Clinical applications and challenges
- References
- Further reading
- Chapter 3 Tools and technologies for biomarker discovery
- Abstract
- 3.1 Introduction
- 3.2 Applicable tools and databases used in biomarker discovery
- 3.3 Advances and challenges
- 3.4 Conclusion
- Funding
- Data availability statement
- Declaration of competing interest
- References
- Chapter 4 Genomic biomarkers: unraveling the DNA of cancer
- Abstract
- 4.1 Introduction
- 4.2 Genomic profiling in cancer
- 4.3 Types of genomic biomarkers
- 4.4 Genomic biomarkers in cancer diagnosis
- 4.5 Genomic biomarkers in cancer prognosis
- 4.6 Genomic biomarkers in cancer treatment
- 4.7 Case studies
- 4.8 Challenges and limitations of using biomarkers in cancer research
- 4.9 Future directions in genomic biomarkers
- 4.10 Conclusion
- Abbreviation
- References
- Chapter 5 Proteomics and protein biomarkers in oncology
- Abstract
- 5.1 Introduction
- 5.2 Techniques in proteomic analysis
- 5.3 Isotope-coded affinity tags
- 5.4 LC-MS/MS
- 5.5 Imaging MS
- 5.6 Free flow electrophoresis
- 5.7 Challenges in proteomic studies
- 5.8 Proteomic biomarkers in different types of cancers
- 5.9 Renal cell carcinoma
- 5.10 Colorectal cancer
- 5.11 Pancreatic cancer
- 5.12 Prostate cancer
- 5.13 Esophageal squamous cell carcinoma
- 5.14 Bladder cancer
- 5.15 Predictive and prognostic biomarkers for cancer
- 5.16 Conclusions
- References
- Chapter 6 Metabolomics: metabolic signatures in cancer biomarkers
- Abstract
- 6.1 Introduction
- 6.2 Reprogramming of metabolism is a key feature for survival of cancer cells
- 6.3 Metabolomics in cancer
- 6.4 Metabolic biomarkers in cancer
- 6.5 Metabolomics as a therapeutic target in cancer
- 6.6 Conclusion
- References
- Chapter 7 Biomarker validation: challenges and regulatory perspectives
- Abstract
- 7.1 Introduction
- 7.2 Validation of cancer biomarkers
- 7.3 Cancer biomarker application in various cancers
- 7.4 Cancer biomarker regulatory pathway
- 7.5 Conclusion
- References
- Chapter 8 Clinical trials and studies for biomarker evaluation
- Abstract
- 8.1 Introduction
- 8.2 Biomarker-driven oncology clinical trial
- 8.3 Issues and Prospects
- References
- Chapter 9 Early detection and diagnostic biomarkers
- Abstract
- 9.1 Introduction
- 9.2 Types of cancer biomarkers
- 9.3 Technologies for biomarker discovery
- 9.4 Clinical applications of diagnostic biomarkers
- 9.5 Challenges and future directions
- 9.6 Liquid biopsy: a noninvasive frontier in early detection
- 9.7 Biomarker-based multicancer early detection
- 9.8 Conclusion
- References
- Chapter 10 Prognostic biomarkers: predicting disease outcomes
- Abstract
- 10.1 Introduction
- 10.2 Prognostication
- 10.3 Classification
- References
- Chapter 11 Predictive biomarkers: guiding personalized cancer therapies
- Abstract
- 11.1 Introduction
- 11.2 Predictive biomarker principles
- 11.3 Technological advancements
- 11.4 Dynamic nature of cancer and adaptive treatment strategies
- 11.5 Collaboration in advancing biomarker explore
- 11.6 Case studies and clinical trials
- 11.7 Future perspective
- 11.8 Conclusion
- References
- Chapter 12 Monitoring treatment response with cancer biomarkers
- Abstract
- 12.1 Introduction
- 12.2 How cancer biomarkers reflect treatment response
- 12.3 Types of cancer biomarkers used in monitoring treatment response
- 12.4 Technologies and techniques for biomarker detection
- 12.5 Clinical applications of biomarkers in monitoring treatment response
- 12.6 Challenges and limitations in biomarker monitoring
- 12.7 Conclusion
- References
- Chapter 13 Ethical considerations in biomarker research and application
- Abstract
- 13.1 Introduction
- 13.2 Informed consent in biomedical research
- 13.3 Privacy and confidentiality concerns
- 13.4 Clinical translation of biomarkers
- 13.5 Incidental findings in biomarker research
- 13.6 Genomic biomarkers and ethical concerns
- 13.7 Ethical implication of AI and machine learning in biomarker research
- 13.8 Ethical framework and guidelines for biomedical research
- 13.9 Conclusion
- 13.10 AI disclosure
- References
- Chapter 14 Challenges and future directions in biomarker development
- Abstract
- 14.1 Introduction
- 14.2 What makes a good biomarker?
- 14.3 Classification
- 14.4 Specimens for the investigation of biomarkers
- 14.5 Challenges and future directions
- 14.6 Diabetes biomarkers
- 14.7 Renal disease biomarkers
- 14.8 Inflammatory bowel disease biomarkers
- 14.9 Pulmonary disease biomarkers
- 14.10 Conclusion
- Acknowledgment
- References
- Chapter 15 Success stories: impactful applications of cancer biomarkers
- Abstract
- Graphical abstract
- 15.1 Introduction
- 15.2 Cancer biomarkers: an overview
- 15.3 The process of identifying and validating biomarkers
- 15.4 Role of biomarkers in monitoring treatment response
- 15.5 Types of biomarkers for monitoring
- 15.6 Success stories: impactful applications of clinical relevance
- 15.7 Success stories: case studies and clinical trials
- 15.8 Highlight and notable biomarkers in current use in monitoring cancer treatment
- 15.9 Challenges in clinical implementation
- 15.10 Regulatory and ethical considerations
- 15.11 Discussion
- 15.12 Conclusion
- Acknowledgment
- Author contributions
- Declarations
- Conflict of interest
- References
- Chapter 16 Shaping future diagnostics: advances and innovations in cancer biomarker science
- Abstract
- 16.1 Introduction
- 16.2 Type of biomarkers and advancements
- 16.3 Technologies using
- 16.4 Trends and innovation in detecting biomarkers
- 16.5 Conclusion
- References
- Index
- Edition: 1
- Published: April 14, 2025
- No. of pages (eBook): 400
- Imprint: Elsevier
- Language: English
- Hardback ISBN: 9780443292798
- eBook ISBN: 9780443292804
PP
Pranav Kumar Prabhakar
Dr. Pranav Kumar Prabhakar is currently working as a Professor in the Department of Biotechnology at Nagaland University, Kohima, Nagaland, India. He has been listed among the World’s Top 2% Scientists (as published by Stanford University, USA, in 2021, 2022, 2023, and 2024). He earned his PhD in Biotechnology from IIT Madras. His primary research interests include elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He also serves as an editorial board member and reviewer for several reputed national and international journals. Dr. Pranav has received various honors, including a travel grant to attend ATTD 2009 in Greece, sponsored by the Indian Institute of Technology Madras and the Council for Scientific and Industrial Research (CSIR), and approved by the Department of Science and Technology (DST). He has published over 115 research articles in journals, authored or edited 17 books, contributed more than 40 book chapters, and delivered 9 oral and poster presentations at scientific meetings.
Affiliations and expertise
Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland-797004, IndiaRead The Potential of Cancer Biomarkers on ScienceDirect